The estimated Net Worth of Stanley C Erck is at least $6.47 Million dollars as of 14 December 2022. Mr. Erck owns over 6,966 units of Novavax stock worth over $476,999 and over the last 16 years he sold NVAX stock worth over $3,553,041. In addition, he makes $2,438,560 as President, Chief Executive Officer, and Director at Novavax.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Erck NVAX stock SEC Form 4 insiders trading
Stanley has made over 27 trades of the Novavax stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 6,966 units of NVAX stock worth $85,612 on 14 December 2022.
The largest trade he's ever made was selling 424,778 units of Novavax stock on 30 March 2016 worth over $2,204,598. On average, Stanley trades about 21,842 units every 93 days since 2008. As of 14 December 2022 he still owns at least 38,812 units of Novavax stock.
You can see the complete history of Mr. Erck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stanley Erck biography
Stanley C. Erck is President, Chief Executive Officer, Director of the Company. He was President and Chief Executive Officer of Novavax, Inc. since April 2011 and a Director since June 2009, and previously served as Executive Chairman from February 2010 to April 2011 and Interim Chief Financial Officer from November 2017 to March 2018. From 2000 to 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International. Mr. Erck serves as a member of the boards of MaxCyte, Inc. and MDBio Foundation. Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago.
What is the salary of Stanley Erck?
As the President, Chief Executive Officer, and Director of Novavax, the total compensation of Stanley Erck at Novavax is $2,438,560. There are no executives at Novavax getting paid more.
How old is Stanley Erck?
Stanley Erck is 72, he's been the President, Chief Executive Officer, and Director of Novavax since 2018. There are 2 older and 20 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
What's Stanley Erck's mailing address?
Stanley's mailing address filed with the SEC is C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG, MD, 20878.
Insiders trading at Novavax
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
What does Novavax do?
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
What does Novavax's logo look like?
Complete history of Mr. Erck stock trades at Biocryst Pharmaceuticals and Novavax
Novavax executives and stock owners
Novavax executives and other stock owners filed with the SEC include:
-
Stanley Erck,
President, Chief Executive Officer, Director -
Gregory Glenn,
President, Research and Development -
John Trizzino,
Executive Vice President, Chief Commercial Officer, Chief Business Officer -
John Herrmann,
Executive Vice President, Chief Legal Officer -
Stanley Charles Erck,
Pres, CEO & Director -
Dr. Gregory M. Glenn,
Pres of R&D -
John Joseph Trizzino B.S., M.B.A.,
Exec. VP and Chief Bus. & Commercial Officer -
John A. Herrmann III,
Exec. VP, Chief Legal Officer & Corp. Sec. -
James Young,
Independent Chairman of the Board -
Michael McManus,
Independent Director -
Gary Evans,
Independent Director -
Richard Douglas,
Independent Director -
Rachel King,
Independent Director -
Gregory Covino,
Chief Financial Officer, Executive Vice President -
David Mott,
Independent Director -
Rajiv Modi,
Director -
Gregg Alton,
Director -
Brian Webb,
Senior Vice President - Manufacturing -
Brian Rosen,
Senior Vice President - Commercial Strategy -
Jody Lichaa,
Senior Vice President - Quality Assurance -
Filip Dubovsky,
Senior Vice President, Chief Medical Officer -
Silvia Taylor,
Senior Vice President of Investor Relations and Corporate Affairs -
Frank Czworka,
Senior Vice President - Global Sales -
Ben Machielse,
Executive Vice President - CMC -
Jill Hoyt,
Chief Human Resource Officer, Executive Vice President -
Troy Morgan Esq., J.D.,
Sr. VP & Chief Compliance Officer -
Troy Morgan Esq.,
Sr. VP & Chief Compliance Officer -
Silvia Taylor M.B.A., MBA,
Sr. VP of Global Corp. Affairs & Investor Relations -
Biegie Lee,
Sr. VP & Chief Information Officer -
Dr. Gale E. Smith,
Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist -
Richard P. Crowley,
Exec. VP & COO -
James Patrick Kelly C.F.A.,
Exec. VP, CFO & Treasurer -
Richard J Rodgers,
-
Margaret G Mcglynn,
-
Gail Boudreaux,
Director -
Barclay A Phillips,
SVP, Chief Financial Officer -
Mark J Casey,
EVP, CLO & Corporate Secretary -
Mitchell J Kelly,
Director -
Susan B Bayh,
Director -
Ford R Lynch,
Sr. VP Marketing and Sales -
John A Lambert,
Director -
Thomas Scott Johnston,
Vice President, Strategy -
Pharmaceuticals Inc King,
10% owner -
John O Jr Marsh,
Director -
Strategic Investments Llcgr...,
-
Denis M Odonnell,
Director -
Ronlad H Walker,
Director -
Frederick W Driscoll,
VP, CFO & Treasurer -
James B Tananbaum,
Director -
Evdoxia E Kopsidas,
Dir.Fin.,Int.Princ.Acctg.Off. -
Jim Robinson,
VP,Technical & Qual. Operation -
D Craig Wright,
Chief Scientific Officer -
Patricia Hall,
Chief Accounting Officer -
Nelson M Sims,
President/CEO -
Raymond Joseph Hage,
VP - Business Development -
Russell P Wilson,
SVP, Business Development -
Len F Stigliano,
VP, CFO and Treasurer -
Ann P Mcgeehan,
General Counsel/Secr -
Timothy Jon Hahn,
SVP, Manufacturing & PD -
Pharmaceuticals Ltd Satelli...,
-
Dennis W Genge,
VP, Treasurer,CFO -
J Michael Md Lazarus,
Director -
Penny Heaton,
Chief Medical Officer -
Jeffrey Wayne Church,
VP, CFO, Treasurer & Corp. Sec -
Rahul Singhvi,
Sr VP, COO -
Thomas P Monath,
Director -
Elaine O'hara,
EVP, Chief Strategy Officer -
John C Jacobs,
President and CEO -
James Patrick Kelly,
EVP, CFO and Treasurer